Inmune Bio reported net income of -$1.37M for the quarter ended Jun 2026. This income statement covers 35 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||||||
| Revenue | 0.01M | 0.16M | 0.16M | 0.02M | 0.10M | 0.10M | 0.04M | 0.05M | 0.04M | 0.03M | 0.01M | 0.05M | |||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 6.52M | 7.07M | 4.31M | 4.19M | 5.16M | 3.41M | 4.13M | 4.15M | 5.99M | 6.01M | 8.69M | 7.05M | 10.07M | 7.35M | 7.64M | 5.80M | 4.89M | 2.33M | 3.64M | -0.80M | |||||||||||||||
| Selling, General & AdministrativeSG&A | 2.52M | 2.12M | 2.33M | 2.21M | 2.38M | 2.33M | 2.33M | 2.31M | 2.59M | 2.40M | 2.34M | 2.81M | 2.22M | 2.11M | 2.32M | 2.25M | 2.55M | 3.15M | 2.17M | 2.28M | |||||||||||||||
| Other Operating ExpensesOther Opex | -0.42M | -0.11M | -0.09M | -0.01M | 0.12M | 16.51M | |||||||||||||||||||||||||||||
| Operating ExpensesOpex | 9.04M | 9.19M | 6.64M | 6.40M | 7.54M | 5.74M | 6.46M | 6.46M | 8.57M | 8.41M | 11.03M | 9.87M | 12.29M | 9.47M | 9.96M | 24.57M | 7.43M | 5.47M | 5.81M | 1.48M | |||||||||||||||
| Operating IncomeOp. Inc | -9.02M | -9.03M | -6.48M | -6.39M | -7.44M | -5.64M | -6.42M | -6.41M | -8.53M | -8.38M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| EBIT | -9.02M | -9.03M | -6.48M | -6.39M | -7.44M | -5.64M | -6.42M | -6.41M | -8.53M | -8.38M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.44M | 0.64M | 0.42M | 0.45M | 0.28M | 0.19M | 0.11M | 0.09M | 0.04M | 0.03M | |||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | |||||||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.01M | 0.17M | |||||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.44M | -0.64M | -0.42M | -0.04M | -0.03M | 0.12M | 0.19M | 0.25M | 0.17M | 0.11M | 0.96M | 0.21M | 0.41M | 0.20M | |||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||
| EBT | -9.46M | -9.67M | -6.90M | -6.84M | -7.72M | -5.83M | -6.54M | -6.50M | -8.56M | -8.41M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Profit After TaxPAT | -9.53M | -9.55M | -6.90M | -6.84M | -8.17M | -5.39M | -6.54M | -6.50M | -8.59M | -8.47M | -11.03M | -9.75M | -12.42M | -9.00M | -9.74M | -24.61M | -6.47M | -5.24M | -5.41M | -1.37M | |||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -9.46M | -9.67M | -6.90M | -6.84M | -7.72M | -5.83M | -6.54M | -6.50M | -8.56M | -8.41M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -9.46M | -9.67M | -6.90M | -6.84M | -7.72M | -5.83M | -6.54M | -6.50M | -8.56M | -8.41M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -9.46M | -9.67M | -6.90M | -6.84M | -7.72M | -5.83M | -6.54M | -6.50M | -8.56M | -8.41M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Net Income towards Common StockholdersNet Income | -9.46M | -9.67M | -6.90M | -6.84M | -7.72M | -5.83M | -6.54M | -6.50M | -8.56M | -8.41M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.55 | -0.60 | -0.39 | -0.38 | -0.43 | -0.33 | -0.36 | -0.36 | -0.48 | -0.47 | -0.61 | -0.51 | -0.61 | -0.47 | -0.44 | -1.05 | -0.28 | -0.22 | -0.22 | -0.06 | |||||||||||||||
| EPS (Diluted) | -0.55 | -0.60 | -0.39 | -0.38 | -0.43 | -0.33 | -0.36 | -0.36 | -0.48 | -0.47 | -0.61 | -0.51 | -0.61 | -0.47 | -0.44 | -1.05 | -0.28 | -0.22 | -0.22 | -0.06 | |||||||||||||||
| Shares Outstanding | 17.33M | 16.13M | 17.87M | 17.95M | 17.95M | 17.93M | 17.95M | 17.95M | 18.01M | 17.98M | 18.03M | 19.31M | 20.19M | 19.94M | 22.50M | 23.30M | 26.59M | 24.76M | 26.59M | 26.72M | |||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 17.33M | 16.13M | 17.87M | 17.95M | 17.95M | 17.93M | 17.95M | 17.95M | 18.01M | 17.98M | 18.03M | 19.31M | 20.19M | 19.94M | 22.50M | 23.30M | 26.59M | 24.76M | 26.59M | 26.72M | |||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 17.84M | 17.84M | 17.95M | 17.95M | 17.95M | 17.95M | 17.95M | 17.95M | 17.95M | 17.95M | 17.95M | 19.71M | 22.17M | 22.28M | 22.93M | 26.59M | 26.59M | 26.59M | 26.59M | 27.65M | |||||||||||||||
| EBITDA | -9.02M | -9.03M | -6.48M | -6.39M | -7.44M | -5.64M | -6.42M | -6.41M | -8.53M | -8.38M | -11.02M | -9.87M | -12.29M | -9.47M | -9.90M | -24.57M | -7.43M | -5.47M | -5.81M | -1.48M | |||||||||||||||
| Interest ExpensesInt Expense | 0.44M | 0.64M | 0.42M | 0.45M | 0.28M | 0.19M | 0.11M | 0.09M | 0.04M | 0.03M |